MENU
APR 02, 2020 6:00 AM PDT

A Multi-Omic Approach to Detection and Characterization of Viral Pathogens and Their Impact on the Immune System

Sponsored by: Fluidigm
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Director, Microfluidics Product Management, Fluidigm
    Biography
      Bill Hunt is a Director of Microfluidics Product Management and has been with Fluidigm for four years. Prior to joining Fluidigm, he was a Marketing Director at Celera Corporation where he managed the commercial relationship with Abbott Molecular, Celera's global distribution partner. Bill earned both Bachelor and Master degrees in Genetics and Molecular Biology from the Pennsylvania State University.
    • Chief Science Officer, Fluidigm
      Biography

        Andrew Quong joined the Fluidigm executive team as Chief Science Officer in June, 2019. Previously he was Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute. Frederick National Laboratory is at the forefront of basic, translational and clinical science with a focus on cancer, AIDS and infectious disease. Before joining the Frederick National Laboratory, Quong served as a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University.


      Abstract

      A growing body of researchers around the world is working to mount an aggressive and sustained response to the COVID-19 pandemic. By building on past successes and harnessing insights from current efforts, the scientific community will be better able to detect and characterize pathogens, identify treatments, and prepare for future outbreaks.

      A comprehensive multi-omic approach is required to understand the complex biological mechanisms involved in SARS-CoV-2 infection, improve the ability to detect and characterize the virus, and assess the subsequent impact on the immune system and the response to therapeutic intervention. Fluidigm microfluidics-based genomic analysis tools and mass cytometry capabilities for highly multiplexed immune cell quantitation are uniquely enabling for virus detection and immune profiling of individuals, and will be increasingly important to government and medical institutions. In this presentation, we will describe our genomic analysis solutions for PCR- and NGS-based applications leveraging the benefits of nanoliter-scale automated microfluidics technology. We will also present the best-in-class immune profiling and monitoring capabilities of mass cytometry, powered by our CyTOF® technology. Our discussion will reflect the use of these tools in research efforts currently underway.


      For Research Use Only. Not for use in diagnostic procedures.


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      C.E. CREDITS
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      JUN 17, 2020 1:30 PM PDT
      C.E. CREDITS
      JUN 17, 2020 1:30 PM PDT
      Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
      JUL 22, 2020 10:00 AM PDT
      C.E. CREDITS
      JUL 22, 2020 10:00 AM PDT
      DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
      AUG 25, 2020 8:00 AM PDT
      C.E. CREDITS
      AUG 25, 2020 8:00 AM PDT
      DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
      Loading Comments...
      Show Resources
      Attendees
      • See more